Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Results From the PARADIGM Phase 3 Head-to-Head Trial of Vectibix® (panitumumab) Versus Bevacizumab in Untreated RAS Wild-Type Metastatic Colorectal Cancer* Largest Evaluation of Acquired Resistance to LUMAKRAS®/LUMYKRAS® (sotorasib) in KRAS G12C-mutated Cancers Inform Combination Treatment Approaches THOUSAND OAKS, Calif. , May 26, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present new data from across its broad oncology innovative medicines and biosimilars portfolio and robust pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago and virtually.

NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022

Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?

Apple

AbbVie

Dollar General

ProShares S&P 500 Dividend Aristocrats ETF

Schwab US Dividend Equity ETF

Western Union

The best offense is a good defense., Here are seven retirement stocks to buy that combine modest growth with safe dividends.

7 Retirement Stocks to Buy to Turbocharge Your Savings

J&J's immunology mega-blockbuster loses exclusivity in the U.S. next year -- and Amgen's biosimilar is ready to capitalize.

Could This Biosimilar Drug Candidate Create a Blockbuster for Amgen?

Amgen can be a cornerstone in your portfolio due to its fortress financial strength, secular support, and strong profitability. At its present price levels, a dividend discount reveals a very asymmetric return profile with an upside near 40% but little downside.

Amgen: Safe Harbor In Turbulent Times

Boeing

JPMorgan Chase & Co

Microsoft

These are the best blue-chip stocks to buy now. MMM, AMGN, BA, JPM, and MSFT can make great investments in the coming months.

5 Beaten-Down Blue-Chip Stocks to Buy Now

Amgen Inc. (NASDAQ:AMGN) has been robust lately. The stock established a strong support at the oversold level of $233 in early May.

Should you buy Amgen after robust earnings take stock higher?

Campaign Drives Awareness of Potential Early Symptoms of Psoriatic Arthritis and Empowers People to Take Action THOUSAND OAKS, Calif. , May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis.

AMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS

VanEck Vectors Biotech ETF

Biogen

Gilead Sciences

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

How Are Biotech ETFs Reacting to These Q1 Earnings Releases?

THOUSAND OAKS, Calif. , May 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2022 Bank of America Healthcare Conference at 12:20 p.m.

AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE

Baxter

Quest Diagnostics

Humana

Merck

Zoetis

As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. The post 7 Defensive Dividend Healthcare Stocks to Buy Now appeared first on InvestorPlace.

7 Defensive Dividend Healthcare Stocks to Buy Now

Much of the company's growth isn't coming from its top-selling drugs.

Should Investors Be Worried About Amgen's Q1 Results?

Amgen's recent results were encouraging, with strong underlying volume growth in key franchises. It has a number of growth prospects in its pipeline, including mid- to late-stage drugs in inflammation, oncology, and general medicine.

Amgen: Another Chance To Average Down

Los Angeles, California--(Newsfile Corp. - May 4, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amgen Inc. ("Amgen" or "the Company") (NASDAQ: AMGN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. As part of Amgen's first quarter 2022 earnings release issued on April...

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - May 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amgen Inc. ("Amgen" or "the Company") (NASDAQ: AMGN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. As part of Amgen's first quarter 2022 earnings release issued on April...

Ongoing Investigation Alert: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm

Intel

Kraft Heinz

Walgreens

The Nasdaq has been absolutely obliterated this year, down a stunning 21.2%, which puts the tech-heavy index firmly in bear market territory.

Why the 5 Highest-Yielding Nasdaq Stocks May Be the Best and Safest Value Buys Now

The net net is more black and white for long-term investors.

1 Green Flag and 1 Red Flag for Amgen

THOUSAND OAKS, Calif. , May 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today released its 2021 Environmental, Social & Governance (ESG) report, providing a comprehensive overview of the many ways the Company is doing its part to build a better, healthier world.

AMGEN RELEASES ANNUAL ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT

LOS ANGELES , April 29, 2022 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amgen Inc. ("Amgen" or "the Company") (NASDAQ: AMGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm

Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.

Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute

Amgen, Inc. (NASDAQ: AMGN) shares are trading lower by 6.21% at $233.33 after the company reported first-quarter earnings results. Amgen reported quarterly earnings of $4.25 per share which beat the analyst consensus estimate of $4.15.

Why Amgen Shares Are Trading Lower

Amgen Inc (NASDAQ: AMGN) has recently received a notice of deficiency from the Internal Revenue Service centered on 2013 to 2015.  The agency seeks to increase Amgen's taxable income for the period by an amount that would result in an additional federal tax of approximately $5.1.

Amgen's Q1 Better Than Expected Sales, Profit Overshadowed By Tax Disclosure

Biotech firm Amgen is disputing the claims, which relate to how it accounts for profits from its Puerto Rico operations.

Amgen Falls After Revealing a $7 Billion IRS Tax Bill

Amgen Inc. (NASDAQ:AMGN ) Q1 2022 Results Conference Call April 27, 2022 5:00 PM ET Company Participants Arvind Sood - VP, IR Bob Bradway - Chairman and CEO Peter Griffith - CFO Murdo Gordon - EVP, Global Commercial Operations David Reese - EVP, Research and Development Conference Call Participants Michael Yee - Jefferies Jay Olson - Oppenheimer Goeff Meacham - Bank of America Salveen Richter - Goldman Sachs Matthew Harrison - Morgan Stanley Yaron Werber - Cowen & Company Umer Raffat - Evercore ISI Carter Gould - Barclays Robyn Karnauskas - Truist Mohit Bansal - Wells Fargo Dane Leone - Raymond James Evan Seigerman - BMO Capital Markets Gavin Scott - JPMorgan Colin Bristow - UBS Operator My name is RJ, and I will be your conference facilitator today for Amgen's First Quarter 2022 Financial Results Conference Call. All lines have been placed on mute to prevent any background nose.

News for Amgen Stock (AMGN)